HAMPTON ROADS, Va. - Colorectal cancer (CRC) is the third most common cancer in America with roughly 151,000 cases each year. Natera is a leader in transforming care through personalized genetic testing and diagnostics and offers a variety of tests that help CRC patients monitor their cancer, inform their treatment, and determine their genetic risk for developing CRC. Today on Coast Live, the General Manager of Oncology at Natera, Solomon Moshkevich, discusses the latest treatment options for detecting or monitoring CRC.
Presented by Natera
Learn more at Natera.com